Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. The difference in density between the gas-filled bubbles and the blood around them creates an increased level of contrast visible in the resulting ultrasound image. During echocardiography, activated Perflutren enhances images of the inner edges or borders of the heart, producing an improved image that may enable physicians to better diagnose patients.
Used as an ultrasound contrast imaging in cardiology and radiology.
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Mayo Clinic Minnesota, Rochester, Minnesota, United States
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Mayo Clinic in Rochester, Rochester, Minnesota, United States
University of Colorado Anschutz, Barbara Davis Center, Aurora, Colorado, United States
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
University of Michigan, Ann Arbor, Michigan, United States
Gregory J Czarnota, Toronto, Ontario, Canada
Univeristy of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States
Columbia University Irving Medical Center/NYPH, New York, New York, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.